Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Oncológicas (23)

2024

  1. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges

    Frontiers in Immunology, Vol. 15

  2. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

2023

  1. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

    Hematological oncology

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

  2. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

  3. The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies

    Cancers, Vol. 14, Núm. 5

2021

  1. Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology

    Leukemia Research

  2. Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients

    International Journal of Laboratory Hematology

  3. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

  4. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial

    Cancers, Vol. 13, Núm. 10

2020

  1. A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics

    Blood Cancer Journal, Vol. 10, Núm. 4

  2. Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity

    British Journal of Haematology, Vol. 189, Núm. 4, pp. 672-683

  3. Novel DNMT3A germline variant in a patient with multiple paragangliomas and papillary thyroid carcinoma

    Cancers, Vol. 12, Núm. 11, pp. 1-12

2019

  1. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

    Haematologica, Vol. 104, Núm. 2, pp. 288-296

  2. Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics

    Journal of Molecular Diagnostics, Vol. 21, Núm. 2, pp. 228-240

  3. MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia

    Scientific reports, Vol. 9, Núm. 1, pp. 18630

  4. Minimal residual disease monitoring with next- generation sequencing methodologies in hematological malignancies

    International Journal of Molecular Sciences, Vol. 20, Núm. 11

  5. Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms

    Haematologica, Vol. 104, Núm. 5, pp. 937-946

2017

  1. Minimal residual disease testing for multiple myeloma

    Hematologia, Vol. 8, Núm. 3, pp. 219-227

2015

  1. Conversion, correction, and international scale standardization: Results from a multicenter external quality assessment study for BCR-ABL1 testing

    Archives of Pathology and Laboratory Medicine, Vol. 139, Núm. 4, pp. 522-529